Eton Pharmaceuticals (NASDAQ:ETON) Announces Quarterly Earnings Results, Hits Estimates

Eton Pharmaceuticals (NASDAQ:ETON) issued its quarterly earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), Zacks reports. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $15.29 on Tuesday. The company has a 50-day moving average of $15.40 and a 200-day moving average of $11.35. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $18.41. The company has a market capitalization of $398.32 million, a price-to-earnings ratio of -69.50 and a beta of 1.37.

Wall Street Analyst Weigh In

ETON has been the subject of a number of research analyst reports. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. B. Riley began coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Craig Hallum lifted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.